633 Time to deterioration of patient-reported outcomes in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
Year: 2024
Type: article
Authors: Ingrid Boere, Bhavana Pothuri, Olena Sukhina, Tashanna Myers, Valentina Tuninetti, Angeles Alvarez Secord, Florian Heitz, Paul Nowicki, Annika Auranen, Nicole Nevadunsky, Lucy Gilbert, Michael J. Callahan, Lyndsay Willmott, Michael A. Gold, Matthew A. Powell, Carolyn Mccourt, Veena Vincent, Veronika Simang, Mansoor Raza Mirza, Noelle Cloven
Institutions: Erasmus MC, Erasmus MC Cancer Institute, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, National Academy of Medical Sciences of Ukraine, State Organization «Grigoriev Institute for Medical Radiology and Oncology of the National Academy of Medical Sciences of Ukraine», Baystate Medical Center, University of Turin, Duke Medical Center, Kliniken Essen-Mitte, Baptist MD Anderson Cancer Center, Tampere University, Tampere University Hospital, Montefiore Medical Center, McGill University Health Centre, St Vincent Hospital, Oklahoma Cancer Specialists and Research Institute, Washington University in St. Louis, GlaxoSmithKline (India), GlaxoSmithKline (Germany), Copenhagen University Hospital, Rigshospitalet, Nordic Society of Gynecologic Oncology, Texas Oncology
Language: English
Subfield: Obstetrics and Gynecology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4392634492